Pfizer Inc (NYSE: PFE, LSE: PFZ) and Swiss biopharmaceutical developer Debiopharm Group entered into a co-development agreement to conduct a Phase 3 trial of melanoma treatment candidate tremelimumab (CP675,206). Under the agreement, Debiopharm will assume responsibility for conducting the phase 3 trial while Pfizer retains responsibility for the worldwide commercialization of the compound.
Melanoma is a form of skin cancer which occurs in approximately 69,000 patients in the US each year causing about 9,000 deaths, Pfizer said. The tremelimumab treatment is a fully human anti-CTLA4 monoclonal antibody for an unresectable Stage IV melanoma.
“The continuation of the clinical development of tremelimumab with our partner, Debiopharm, is a demonstration of our commitment to personalized medicine for cancer patients”, Pfizer Oncology president Garry Nicholson commented.
Financial terms of the co-development deal have not been disclosed by either company. http://www.proactiveinvestors.com/companies/news/3520/pfizer-and-debiopharm-seal-co-development-deal-for-melanoma-treatment-3520.html
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
No comments:
Post a Comment